课题基金 / 基金详情

Difference of biological activities and signals between IFN-ζ/limitin and IFN-α

Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
IFN-ζ/limitin 与 IFN-α 生物活性及信号差异
批准号:
15390300
负责人:
ORITANI Kenji
金额:
$9.47万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004

项目摘要

项目成果

ORITANI Kenji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our identified limitin has a sequence homology with type I IFNs and displays antiviral activity against several viruses. In addition, it can bind to IFN-α/βR and induces some effectors as IFN-α and IFN-β. Based on these facts, limitin has been considered as a novel type I IFN with the designation of IFN-ζ by the Nomenclature Committee of the International Society for Interferon and Cytokine Research. Both IFN-ζ/limitin and IFN-α were titrated with a cytopathic effect dye binding assay in encephalo myocarditis virus-infected L929 cells. Half-maximal protection was achieved with 30 pg/ml of IFN-ζ/limitin and with 30-300 pg/ml of several subtypes of IFN-αs. These titrated IFNs were used for point-by-point comparison of their biological activities and signals. IFN-ζ/limitin showed antitumor, immunomodulatory, and antiviral activities as strong as IFN-α. However, IFN-ζ/limitin did not suppress CFU-GM or BFU-E colony formation while IFN-α did. Much higher concentrations of IFN-ζ/limitin than … More IFN-α were required for the suppression of CFU-IL7 and CFU-Meg colony formation. Similarly, approximately 30% of CFU-GM and 50% of BFU-E in bone marrow were reduced when 4,000 international unit (IU)/body/day of IFN-α was injected, while there was no influence on these progenitors even when IFN-ζ/limitin was injected at 40,000 IU/body/day. With regard to signaling, similar signaling molecules are used between IFN-ζ/limitin and IFN-α, but there are some differences. In fibroblasts, IRF-1-dependent pathway is more critical for IFN-ζ/limitin than IFN-α to induce antiviral state and to induce ISRE promoter activity. In addition, higher dose of IFN-ζ/limitin is required for the induction of Daxx in megakaryocytes than IFN-α. We also analyzed a role of Daxx in apoptosis, in addition, identified DMAP1 and TSG101 as novel Daxx-associated proteins. As described above, we have clarified characters of IFN-ζ/limitin in biological activities and signaling. To our regret, we could not isolate the human homologue of IFN-ζ/limitin. To make an engineered cytokine with some features of IFN-ζ/limitin, we have constructed IFN-a cDNA with mutations based on the differences of sequence between IFN-ζ/limitin and IFN-α. Less
期刊论文(60)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1128/jvi.77.17.9622-9631.2003
发表时间: 2003-09-01
期刊: JOURNAL OF VIROLOGY
影响因子: 5.4
作者: [Kawamoto, SI, Oritani, K, Matsuzawa, Y]
通讯作者: Matsuzawa, Y
Interferon-zeta/limitin : novel type I interferon that displays a narrow rane of biological activity.
Interferon-zeta/limitin:新型 I 型干扰素,具有窄范围的生物活性。
DOI: --
发表时间: 2004
期刊: Int J Hematol. 80
影响因子: --
作者: [Oritani K, et al.]
通讯作者: et al.
DOI: 10.1016/j.bbrc.2004.02.126
发表时间: 2004-04
期刊: Biochemical and biophysical research communications
影响因子: 3.1
作者: [R. Muromoto;K. Sugiyama;Tetsuya Yamamoto;K. Oritani;Kazuya Shimoda;T. Matsuda]
通讯作者: R. Muromoto;K. Sugiyama;Tetsuya Yamamoto;K. Oritani;Kazuya Shimoda;T. Matsuda
Physical and functional interactions between Daxx and DNA methyltransferase1-accociated protein, DMAP1.
Daxx 和 DNA 甲基转移酶 1 相关蛋白 DMAP1 之间的物理和功能相互作用。
DOI: --
发表时间: 2004
期刊: J Immunol. 172
影响因子: --
作者: [Azuma T, et al., Muromoto R et al., Saida T., Muromoto R et al.]
通讯作者: Muromoto R et al.
24
    Analysis of in vivo effects of possible immune regulatory moleculesfor artificial management of immune systems
    • 批准号:
      22591062
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2010
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Development of a novel interferon with mild adverse effects
    • 批准号:
      19390264
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.98万
    • 财政年份:
      2007
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Establishment of a novel IFN therapy with little side effects
    • 批准号:
      17390277
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.86万
    • 财政年份:
      2005
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    Biological activity of limitin and adiponectin
    • 批准号:
      13671064
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.56万
    • 财政年份:
      2001
    • 负责人:
      ORITANI Kenji
    • 依托单位:
    海外基金